Xenon Pharmaceuticals Inc. (XENE)
NEUTRALファンダメンタル
29
株価
$60.53
時価総額
$5.88B
パート1 · 企業の価値
概要
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
貸借対照表と流動性
売上高
$8M
2025/12/31に終了した会計年度
純利益
$-346M
2025/12/31に終了した会計年度
フリーキャッシュフロー
$-280M
自己資本合計
$582M
負債合計
$51M
流動比率
21.02
利払い倍率
-
負債/EBITDA
-
一株当たり利益（EPS）
売上高と純利益
フリーキャッシュフロー
収益内訳
財務推移表
利益率の推移
負債の推移
負債の重さ
成長率グリッド
成長率 — 売上高
適正価値の推定
適正価値
$81.30
現在株価
$60.53
安全マージン
+25.5%
適正価値レンジ
$77.23 - $85.36
推定方法
バリュエーション指標
P/E レシオ
-
ROE
-59.5%
P/B レシオ
4.72
P/FCF
-
粗利益率
-
ROIC
-27.9%
収益性レーダー
Value Creation (Economic Moat)
ROIC
-27.9%
WACC
8.0%
ROIC − WACC
-35.9 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
ファンダメンタル分析基準
合格（6）
- Price CAGR 22.95%
- Debt/Equity ratio
- Current Ratio
- Low reliance on intangibles
- Analyst Consensus 96% Buy
- Share Dilution 1.9%
不合格（11）
- EPS shows upward trend
- ROIC -27.9%
- P/B Ratio 4.72
- Operating Margin -Infinity%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Overvalued)
- ROE -44.0%
- Revenue Growth 5Y -25.3%
- Earnings Surprise avg 0.5%
- Piotroski F-Score 2/9
データなし（10）
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Net Margin Trend (invalid data)
Piotroski F-スコア
重大な財務上の懸念
利益の質
低品質：会計処理を調査してください
株式希薄化
株式数は安定している
ガバナンス
経営陣
| 氏名 | 役職 | 年齢 |
|---|---|---|
| Mr. Ian C. Mortimer C.M.A., CPA, M.B.A. | President, CEO & Director | 49 |
| Mr. Thomas Patrick Kelly J.D. | Chief Financial Officer | 54 |
| Ms. Andrea DiFabio J.D. | Chief Legal Officer & Corporate Secretary | 57 |
| Dr. Christopher John Kenney M.D. | Chief Medical Officer | 54 |
| Mr. Darren S. Cline M.B.A. | Chief Commercial Officer | 61 |
| Dr. Matthew D. Ronsheim Ph.D. | Chief Operating Officer | 53 |
| Ms. Shelley McCloskey B.A. | Executive Vice President of Human Resources | 65 |
| Dr. Robin P. Sherrington Ph.D. | Executive Vice President of Strategy & Innovation | 64 |
| Dr. James R. Empfield Ph.D. | Executive Vice President of Drug Discovery | 64 |
| Ms. Colleen Alabiso | Senior Vice President of Corporate Affairs | - |
監査リスク
5
取締役会リスク
1
報酬リスク
8
株主権利リスク
3
パート2 · 株価と買い時
この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容：テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。
Latest News
Recent headlines for XENE, sourced from Markets Gazette.
- 3/9/2026POSITIVEXenon Pharmaceuticals Rallies After Pivotal Data Shows Major Drop In Monthly Seizures
Xenon Pharmaceuticals Inc. experienced a significant share price surge following the release of positive Phase 3 clinical trial data for its drug azetukalner. The pivotal study demonstrated a substantial reduction in monthly seizures for patients treated with the drug. This success paves the way for Xenon to file for FDA approval in 2026. The strong clinical results and clear regulatory path are highly encouraging for investors, potentially positioning azetukalner as a significant new treatment option and driving future revenue growth for the company.
via Markets Gazette